October 15, 2021 5:48pm

As I stated in this a.m.’s post, “I’m saying BYE after new highs, fleeing into the safe zone”

Pre-open indication results: 5 Hits and 0 MISS

My version of the session’s “indications” is about what you need to know; it’s what did happen after the opening, mid-day and to the close

An objective, fact and numbers-based narrative

The week in review …

The Dow closed UP +382.20 points (+1.09%); the S&P closed UP +33.11 points (+0.75%) while the Nasdaq closed UP +73.91 points (+0.50%)

 

Henry’omics:

Indexes closed up scoring its biggest weekly percentage gain since June; while the stem, cell and gene therapy sector cratered on Friday.

The three major indexes closed the week higher and are positive on the month.

For the week, the Nasdaq jumped 2.2% while the small-cap Russell 2000 gained 1.6%, despite slipping on Friday.

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what’s happening …

  • Friday opened positive at 16/15, 3 flats and 1 acquired, flipped negative at the mid-day at 11/21, 2 flats and 1 acquired, ending with a negative close of 7/25, 2 flats and 1 acquired;
  • Thursday opened positive at 28/3, 3 flats and 1 acquired, stayed positive at the mid-day at 26/7 and 1 acquired, ending with a positive close of 22/10, 2 flats and 1 acquired;
  • Wednesday opened positive at 21/13 and 1 acquired, strayed neutral at the mid-day at 17/17 and 1 acquired, ending with a positive close of 19/14, 1 flat and 1 acquired;
  • Tuesday opened positive at 26/6, 2 flats and 1 acquired, stayed positive at the mid-day at 21/12, 1 flat and 1 acquired, ending with a positive close of 7/24, 3 flats and 1 acquired;
  • Monday opened positive at 18/15, 1 flat and 1 acquired, stayed positive at the mid-day at 24/8, 2 flats and 1 acquired, ending with a positive close of19/14, 1 flat and 1 acquired;

 

RegMed Investors’ (RMi) pre-open: “I’m saying BYE after new highs fleeing into the safe zone. Four (4) sector positive closes in a row and six (6) positive closes out of ten (10) sessions.” … https://www.regmedinvestors.com/articles/12140

 

Pre-open indication results: 5 Hits: < Biostage (BSTG +$0.035 with 528 shares traded); SELL into Strength:  Alnylam Pharmaceuticals (ALNY -$0.73), Fate Therapeutics (FATE -$1.27), Cellectis SA (CLLS +$0.13), CRISPR Therapeutics (CRSP - $1.70)> and 0 MISS

 

Key Metric - volume:

  • Sector volume was LOW with 4 of the 7-upside having higher than the 3-month average volume with INCREASED volume of 2 of 25-downside having higher than the 3-month average volume;

Largest upside volume:

  • bluebird bio (BLUE +0.29 – 2.043 m shares traded)
  • Ionis Pharmaceutical (IONS +0.61 – 1.812 m shares traded)

 

There are clear winners and losers

Jumping with share pricing momentum (7 of 7):

  • BioLife Solutions (BLFS +$0.93 after Thursday’s +$1.13, Wednesday’s +$0.42, Tuesday’s +$0.59 and Monday’s -$0.52),
  • Ionis Pharmaceuticals (IONS +$0.61 after Thursday’s +$0.93, Wednesday’s -$0.45, Tuesday’s -$0.40 and Monday’s +$0.32),
  • bluebird bio (BLUE +$0.29),
  • MiMedx (MDXG +$0.24),
  • Cellectis SA (CLLS +$0.13 after Thursday’s +$1.08 and Wednesday’s +$0.47),
  • Verastem VSTM +$0.01),
  • Homology Medicine (FIXX +$0.01 after Thursday’s -$0.01 and Wednesday’s -$0.37),

Hammered in today’s market (10 of 25):

  • CRISPR Therapeutics (CRSP -$1.70 after Thursday’s +$1.93, Wednesday’s -$5.82, Tuesday’s +$1.94 and Monday’s +$2.02),
  • ReNeuron (RENE.L -$1.50 after Thursday’s +$6.00, Wednesday’s -$6.00, Tuesday’s +$2.50 and Monday’s +$20.70)
  • Global Blood Therapeutics (GBT -$1.41 after Thursday’s -$0.07 after Wednesday’s +$0.63, Tuesday’s +$1.07 and Monday’s +$0.70),
  • Intellia Therapeutics (NTLA -$1.28 after Thursday’s +$6.42, Wednesday’s -$2.73, Tuesday’s +$2.15 and Monday’s +$5.22),
  • Fate Therapeutics (FATE -$1.27 after Thursday’s +$2.36, Wednesday’s +$1.08, Tuesday’s +$2.52 and Monday’s +$1.62)
  • Ultragenyx (RARE -$1.00 after Thursday’s -$0.08, Wednesday’s -$1.71, Tuesday’s +$1.80 and Monday’s -$0.65),
  • Sage Therapeutics (SAGE -$0.95),
  • Editas Medicine (EDIT -$0.93 after Thursday’s +$1.08, Wednesday’s +$0.34 and Tuesday’s +$0.89),
  • Alnylam Pharmaceuticals (ALNY -$0.73 after Thursday’s +$5.40, Wednesday’s +$0.45, Tuesday’s -$1.09 and Monday’s +$0.83)
  • uniQure NV (QURE -$0.58),

Closing Flat:

2 – Athersys (ATHX), Caladrius Biosciences (CLBS) and 1 - Stemline Therapeutics (STML) – acquired

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Friday the IBB closed down -0.51% and XBI closed down -1.59%
  • Thursday the IBB closed up +1.47% and XBI closed up +1.67%
  • Wednesday the IBB closed up +0.58% and XBI closed up +0.42%
  • Tuesday the IBB closed up +0.12% and XBI closed up +0.44%
  • Monday, the IBB closed down -0.35% and XBI closed up +0.51%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Friday was down -0.56 points or -3.32% at 16.30
  • Thursday was down -1.78 points or -9.55% at 16.86
  • Wednesday was down -1.21 points or -6.10% at 18.64
  • Tuesday was down -0.15 points or -0.75% at 19.85
  • Monday was up +1.23 points or +6.55% at 20.00

 

October, the first month of Q3/21:

Friday closed negative with 7 advancers, 25 decliners, 2 flats and 1 acquired

Thursday closed positive with 22 advancers, 10 decliners, 2 flats and 1 acquired

Wednesday closed positive with 19 advancers, 14 decliners, 1 flat and 1 acquired

Tuesday closed positive with 21 advancers, 14 decliners, 2 flats and 1 acquired

Monday (10/11) closed positive with 19 advancers, 14 decliners, 1 flat and 1 acquired

Friday closed negative with 7 advancers, 24 decliners, 3 flats and 1 acquired

Thursday closed positive with 22 advancers, 12 decliners and 1 acquired

Wednesday closed negative with 9 advancers, 23 decliners, 2 flats and 1 acquired

Tuesday closed positive with 17 advancers, 16 decliners, 1 flat and 1 acquired

Monday (10/4) closed negative with 5 advancers, 28 decliners, 1 flat and 1 acquired

Friday (10/1) closed negative with 4 advancers, 28 decliners, 2 flats and 1 acquired

 

 

The BOTTOM LINE: I hope you enjoyed the highs … I said a “watch-out” was due

A Watch-Out - the Nasdaq jumped above its 21-day moving average and last week's highs, moving to just shy of its 50-day line. The S&P 500 and Dow Jones bounced back above their 21-day lines and closed just above the 50-day line.

We're starting to get into an earnings-driven down slide. We'll be seeing the results in the next couple of weeks. Coming, EPS (earnings-per-share) risk; but, eyeing muted returns for the rest of 2021 after quarterly releases.

Once again, a large number of stem, cell and gene therapy stocks showed strength within lackluster meaning – low volume.

There are a lot of headwinds out there as we embark on corporate earnings, and traders will be looking for any and all indications of guidance.

Reiterating, “the stem, cell and gene therapy sector is still seen as vulnerable to extreme moves in either direction, overbought and oversold categories as risk stimulates the susceptibility!”

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

 

The week in review …

Monday:

RegMed Investors’ (RMi) pre-open: expectation, sector stocks set for diving start … https://www.regmedinvestors.com/articles/12132

RegMed Investors’ (RMi) closing bell: sector’s incline accelerates as session progresses … https://www.regmedinvestors.com/articles/12133

 

Tuesday:

RegMed Investors’ (RMi) pre-open: is the sector running into a wall of resistance? … https://www.regmedinvestors.com/articles/12134

RegMed Investors’ (RMi) closing bell: love the upside but, the highs won’t last as Q3 results are being prepared for disposition … https://www.regmedinvestors.com/articles/12135

 

Wednesday:

RegMed Investors’ (RMi) pre-open: mixed sector vibes … https://www.regmedinvestors.com/articles/12136

RegMed Investors’ (RMi) closing bell: a broad-brush approach and sector review … https://www.regmedinvestors.com/articles/12137

 

Thursday:

RegMed Investors’ (RMi) pre-open: a lackluster sector, yet up … https://www.regmedinvestors.com/articles/12138

RegMed Investors’ (RMi) closing bell: hangin’ with the upside although low volume is a problem … https://www.regmedinvestors.com/articles/12139

 

Friday:

RegMed Investors’ (RMi) pre-open: I’m saying BYE after new highs fleeing into the safe zone … https://www.regmedinvestors.com/articles/12140

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.